Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00969332 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
A Phase 2 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00969332 is a Phase 2 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 62 participants.
The verdict
NCT00969332, a Phase 2 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate if intravenous fish oil, commercially available as Omegaven, safely and effectively reverses parenteral nutrition associated cholestasis in children.
Interventions
- DRUG Omegaven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-08 |
| Est. Completion | 2019-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00969332
The ClinicalTrials.gov registry entry for NCT00969332 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omegaven is the first listed.
NCT00969332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00969332 about?
NCT00969332 is a clinical study titled "A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease". The purpose of the study is to investigate if intravenous fish oil, commercially available as Omegaven, safely and effectively reverses parenteral nutrition associated cholestasis in children.
What is the current status of trial NCT00969332?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2009-08. Estimated completion is 2019-02-12.
What interventions are being tested in trial NCT00969332?
The interventions under investigation include: Omegaven (DRUG).
Who is sponsoring clinical trial NCT00969332?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.